Skip to main content
< Back
About
About the conference
App
Organisers & Partners
Latest updates
Press room
Registration
Venue 22
About the venue
Rooms
Call for abstracts
Programme 22
Tracks 22
Speakers 22
Side events 22
Subscribe
days
hours
minutes
seconds
Markets
Sessions
Wednesday, 23 November
10:50
Advances in toxicology
10:50
to
12:20
Central square 2 (C2)
Oral presentation session
Current and future challenges associated with emerging cannabis markets
10:50
to
12:20
Main stage
Structured session
13:20
Assessing the impact of laws and policies regulating illicit drugs on health and society: some insights
13:20
to
14:50
Knowledge market 4 (K4)
Structured session
Policies for regulating cannabis supply in Europe and the US: the need for appropriate monitoring and evaluation
13:20
to
14:50
Knowledge market 1 (K1)
Structured session
15:00
Drug Early Warning Systems – the key to preparedness and response to new psychoactive substances
15:00
to
16:30
Central square 2 (C2)
Structured session
How prepared are monitoring systems to respond to rapidly changing drug markets in regions bordering the European Union?
15:00
to
16:30
Insights zone 4 (I4)
Structured session
Surveillance
15:00
to
16:30
Networking zone 4 (N4)
Short communication session
16:50
Scanner - Understanding the dynamics and consequences of new psychoactive substances in a rapidly changing (online) drug market
16:50
to
18:20
Insights zone 4 (I4)
Structured session
Thursday, 24 November
10:50
Studying illegal drugs in socially embedded markets
10:50
to
12:20
Central square 2 (C2)
Structured session
13:20
New Psychoactive Substances
13:20
to
14:50
Insights zone 4 (I4)
Oral presentation session
Shifting markets and drug trafficking
13:20
to
14:50
Networking zone 2 (N2)
e-poster guided tour
Smoking and e-cigarettes
13:20
to
14:50
Central square 3 (C3)
Oral presentation session
The globalised illicit drug market
13:20
to
14:50
Main stage
Structured session
Friday, 25 November
10:50
Recreational drug use and risk
10:50
to
12:20
Central square 3 (C3)
Oral presentation session
13:20
Changes and trends in how people are buying drugs
13:20
to
14:50
Insights zone 4 (I4)
Oral presentation session
Using innovative data or methods to assess drug markets and drug policy impacts
13:20
to
14:50
Knowledge market 1 (K1)
Oral presentation session
Presentations
Wednesday, 23 November
10:50
Oral presentation
Agreement between self-reported illicit drug use and biological samples: a systematic review and meta-analysis
10:50
to
12:20
Central square 2 (C2)
Chrianna Bharat
Oral presentation
Anti-doping knowledge and educational needs of Finnish pharmacists
10:50
to
12:20
Central square 2 (C2)
Jukka Koskelo
Oral presentation
The implementation of ultra-portable devices for analysis of illicit drug in drug checking service of the Canton of Vaud (Switzerland, CH)
10:50
to
12:20
Central square 2 (C2)
Emilia Gianola
Oral presentation
Characteristics of acute ecstasy-related toxicity in multiple Dutch medical settings, from 2009 through 2018
10:50
to
12:20
Central square 2 (C2)
Lonja Schurmann
Oral presentation
Metabolite profiling of synthetic cathinones: towards the identification of consumption biomarkers in forensic and clinical settings
10:50
to
12:20
Central square 2 (C2)
Alexandra Antunes
13:20
Oral presentation
3. The Swiss pilot trials with cannabis – evaluation after one year
13:20
to
14:50
Knowledge market 1 (K1)
Maya Ackermann
Oral presentation
4. The Dutch closed cannabis supply chain experiment: background, design of the evaluation study and challenges
13:20
to
14:50
Knowledge market 1 (K1)
Margriet van Laar
Discussion
Adapting monitoring and evaluation to the different versions of 'legalisation', while exploring possible common indicators
13:20
to
14:50
Knowledge market 1 (K1)
Brendan Hughes
Oral presentation
5. The U.S. Cannabis Policy Scale: Moving Beyond Dichotomous Measures to Evaluate Impacts of Liberalization Policies on Cannabis and Other Substance Use Outcomes
13:20
to
14:50
Knowledge market 1 (K1)
Rosalie Pacula
Oral presentation
1. Designing a system of monitoring responsible use and distribution of cannabis in Malta
13:20
to
14:50
Knowledge market 1 (K1)
Mariella Dimech
Oral presentation
2. Measuring the impacts of a new cannabis regulation in Luxembourg: the need for valid data collection methods
13:20
to
14:50
Knowledge market 1 (K1)
Nadine Berndt
Oral presentation
1. Drug laws indicators through the leximetric approach and relationship with effectiveness: the example of Italy in the period 1991-2018
13:20
to
14:50
Knowledge market 4 (K4)
Carla Rossi
Oral presentation
2. Hospitalization risk profile of opioids users
13:20
to
14:50
Knowledge market 4 (K4)
Giada Minelli
Oral presentation
3. Using Supply Indicators in the Evaluation of Drug Supply Reduction – Challenges and Opportunities
13:20
to
14:50
Knowledge market 4 (K4)
Nicola Singleton
Oral presentation
4. Estimating the size of the of illicit drug market – a critical review
13:20
to
14:50
Knowledge market 4 (K4)
Robin Udrisard
Oral presentation
5. Estimating the costs of the criminal justice system
13:20
to
14:50
Knowledge market 4 (K4)
Francesco Fabi
Discussion
Integrating indicators and estimates
13:20
to
14:50
Knowledge market 4 (K4)
Peter H. Reuter
15:00
Oral presentation
4. Key developments in drug markets of Eastern European Neighbourhood Policy (ENP) countries
15:00
to
16:30
Insights zone 4 (I4)
Daan Van der Gouwe
Short communication
The Unit of Cannabis: from a systematic review to a NIDA recommendation
15:00
to
16:30
Networking zone 4 (N4)
María Teresa Pons-cabrera
Short communication
A longitudinal study of a drug checking service for patrons of Boom Festival 2018: behavioral outcomes at individual and group levels.
15:00
to
16:30
Networking zone 4 (N4)
Helena Valente
Short communication
Using Reddit Social Media Data to Uncover Self-medication and Drug Use Trends among Opioid Users: Semi-automated Natural Language Processing Approach.
15:00
to
16:30
Networking zone 4 (N4)
Georgiy Bobashev
Short communication
Findings from novel methods of surveillance for fentanyl and novel psychoactive substances within Supervised Injecting Facilities
15:00
to
16:30
Networking zone 4 (N4)
Suzanne Nielsen
Oral presentation
1. Key developments in drug markets of North Africa and Middle East
15:00
to
16:30
Insights zone 4 (I4)
Emadeddin Badi
Short communication
Detection of Potent 'Nitazene' Synthetic Opioids by a networked drug checking service in Toronto, Ontario, Canada
15:00
to
16:30
Networking zone 4 (N4)
Kristy Scarfone
Oral presentation
3. Key developments in drug markets of Western Balkans
15:00
to
16:30
Insights zone 4 (I4)
Robert Patrancus,
Katerina Skarupova
Short communication
Access to medical cannabis in Brazil: informal regulation via patient associations as a social movement
15:00
to
16:30
Networking zone 4 (N4)
Paulo J. R. Pereira
Oral presentation
5. Changing drug market requires new priorities for Moldova’s law enforcement authorities
15:00
to
16:30
Insights zone 4 (I4)
Vladislav Cojuhari
Short communication
Method development for monitoring Google-indexed e-shops offering new psychoactive substances (NPS) in The Netherlands.
15:00
to
16:30
Networking zone 4 (N4)
Lavinia Stegemann
Oral presentation
2. Lebanon: responding to drug market changes in crisis situation
15:00
to
16:30
Insights zone 4 (I4)
Zeinab Abbas
Short communication
How to evaluate complex drug policies? A case study of the Belgian drug policy
15:00
to
16:30
Networking zone 4 (N4)
Eva Blomme
Oral presentation
4. NPS Discovery: An Open Access Early Warning System for the United States
15:00
to
16:30
Central square 2 (C2)
Barry K. Logan
Oral presentation
5. International cooperation to address global public health harms caused by novel psychoactive substances while protecting access to medicines
15:00
to
16:30
Central square 2 (C2)
Dilkushi Poovendran
Oral presentation
1. Early warning on emerging drug threats at the international level – opportunities and challenges
15:00
to
16:30
Central square 2 (C2)
Martin Raithelhuber
Oral presentation
2. Global markets, glocal threats: Early warning, preparedness, and response to new psychoactive substances in Europe
15:00
to
16:30
Central square 2 (C2)
Michael Evans-Brown
Oral presentation
3. Early Warning Systems are Critical to Drug Control Strategies to Protect Public Health and Safety
15:00
to
16:30
Central square 2 (C2)
Luli R. Akinfiresoye,
Terrence L. Boos
16:50
Oral presentation
1. Analysis of NPS and drugs purchased on Darknet and Clearnet markets
16:50
to
18:20
Insights zone 4 (I4)
Mireia Ventura
Oral presentation
2. The influence of legislation on the availability of NPS
16:50
to
18:20
Insights zone 4 (I4)
Judith Aldridge
Oral presentation
3. Prevalence of NPS use. Results of the implementation of a standardized survey methodology amongst 25 civil society organization in Europe
16:50
to
18:20
Insights zone 4 (I4)
Jochen Schrooten
Discussion
The importance of the justice programme
16:50
to
18:20
Insights zone 4 (I4)
Koralia Kontou
Introduction
Scanner - Understanding the dynamics and consequences of new psychoactive substances in a rapidly changing (online) drug market
16:50
to
18:20
Insights zone 4 (I4)
Margot Balcaen
Thursday, 24 November
10:50
Oral presentation
1. Synthetic opioids in Sweden: Analyses of public webforum discussions
10:50
to
12:20
Central square 2 (C2)
Kim Moeller
Oral presentation
2. From the jungle to the street: Country-level variation and demographic correlates of cocaine prices
10:50
to
12:20
Central square 2 (C2)
Rasmus Munksgaard
Oral presentation
3. Illegal drug markets on social media: Locally bound actors on global platforms
10:50
to
12:20
Central square 2 (C2)
Silje Anderdal Bakken
Oral presentation
4. How do you become involved in hybrid digital drug markets: Identifying explanations in a qualitative interview study with social media sellers
10:50
to
12:20
Central square 2 (C2)
Jakob Demant
13:20
Oral presentation
Codesigning an Australian National Prompt Response Network for Emerging Drugs
13:20
to
14:50
Insights zone 4 (I4)
Penelope Hill
e-poster
New trends - The role of Montenegrin criminal groups in international drug crime
13:20
to
14:50
Networking zone 2 (N2)
e-poster
Synthetic drug production and trafficking in Belgium
13:20
to
14:50
Networking zone 2 (N2)
Sophia De Seranno
e-poster
Nicotine content, labelling and flavours of e-liquids in Canada: a scan of the online retail market from 2020-2021
13:20
to
14:50
Networking zone 2 (N2)
Kimberly D'Mello
e-poster
How tiny Albania became the continent’s drug trafficking headquarters. What is the best prevention policy?
13:20
to
14:50
Networking zone 2 (N2)
Sonila Bitri
Oral presentation
A qualitative study of people who use new psychoactive substances and harm reduction services in eight countries of Eastern Europe and Central Asia region
13:20
to
14:50
Insights zone 4 (I4)
Eliza Kurcevič
Oral presentation
In vitro pharmacological characterization of recent non-fentanyl synthetic opioids including 2-benzylbenzimidazole ‘nitazene’ opioids
13:20
to
14:50
Insights zone 4 (I4)
Marthe Vandeputte
Oral presentation
Cannabis adulterated with the synthetic cannabinoid receptor agonist MDMB-4en-PINACA and the role of European drug checking services
13:20
to
14:50
Insights zone 4 (I4)
Pieter E. Oomen
e-poster
Exploring the possible human security impact of introducing Blockchain Technologies in Health Canada’s Cannabis supply chain.
13:20
to
14:50
Networking zone 2 (N2)
Stephen Johnson
e-poster
Monitoring online drug markets - The darknet project in Zurich
13:20
to
14:50
Networking zone 2 (N2)
Joël Bellmont
Oral presentation
What will the future nicotine market look like in a post-smoking era?
13:20
to
14:50
Central square 3 (C3)
Karl Erik Lund
Oral presentation
Effectiveness of e-cigarettes for smoking cessation in the German population - a comparison with nicotine replacement therapy and no use of evidence-based support (DEBRA study)
13:20
to
14:50
Central square 3 (C3)
Daniel Kotz
Oral presentation
The lifetime costs and benefits of subsidizing the cost of nicotine replacement therapy in Sweden
13:20
to
14:50
Central square 3 (C3)
Inna Feldman
Oral presentation
Cessation of Smoking Trial in the Emergency Department- interim results
13:20
to
14:50
Central square 3 (C3)
Ian Pope
Oral presentation
Motivation to stop smoking in the German population: recent trends and associated factors (DEBRA study)
13:20
to
14:50
Central square 3 (C3)
Benjamin Borchardt
Oral presentation
The added value of drug checking data in combination with data from online drug monitoring to evaluate NPS market dynamics: the case of 3-MMC in the Netherlands.
13:20
to
14:50
Insights zone 4 (I4)
Laura Smit-rigter
Oral presentation
1. How Robust and Innovative are Illegal Drug Markets?
13:20
to
14:50
Main stage
Peter H. Reuter
Oral presentation
2. To what extent can drug violence indicators tell us something about underlying drug market activity?
13:20
to
14:50
Main stage
Marieke Liem
Oral presentation
4. The geography of drug markets and hotspots of violence
13:20
to
14:50
Main stage
Tuesday Reitano
3. Drug Markets in Afghanistan
13:20
to
14:50
Main stage
David Mansfield
Friday, 25 November
10:50
Oral presentation
Size Matters: Comparing the MDMA content and weight of ecstasy tablets submitted to European drug checking services in 2012-2021
10:50
to
12:20
Central square 3 (C3)
Ruben Vrolijk
Oral presentation
Shifting stages of ATS use and evidence-based intervention for risk reduction
10:50
to
12:20
Central square 3 (C3)
Nienke Liebregts
Oral presentation
Polydrug use typologies of regular ecstasy users visiting electronic dance music events in the United Kingdom and the Netherlands: A Latent Class Analysis.
10:50
to
12:20
Central square 3 (C3)
Ruben Van Beek
Oral presentation
Drug use and harm reduction in techno parties: some lessons learned from 20 years of fieldwork
10:50
to
12:20
Central square 3 (C3)
Fabrice Guilbaud
Oral presentation
New psychoactive substances tested by Energy Control, a community-based service of drug-checking and harm-reduction in Spain
10:50
to
12:20
Central square 3 (C3)
Adrià Quesada
13:20
Oral presentation
Monitoring online illicit drug market during the COVID-19 in Georgia
13:20
to
14:50
Insights zone 4 (I4)
Irma Kirtadze
Oral presentation
Who buys drugs using online sources in Ireland? Findings from the European Web Survey on Drugs
13:20
to
14:50
Insights zone 4 (I4)
Deirdre Mongan
Oral presentation
What can we learn from low-THC cannabis growers in Europe? A comparative transnational study of 1635 small-scale cannabis growers in Italy and Switzerland
13:20
to
14:50
Insights zone 4 (I4)
Davide Fortin
Oral presentation
Brokered Illegal Drug Sales as a Measure of Local Demand
13:20
to
14:50
Insights zone 4 (I4)
Georgiy Bobashev
Oral presentation
Cannabis regulation and fiscal policy: Opportunities for human rights in Colombia
13:20
to
14:50
Knowledge market 1 (K1)
Luis Felipe Cruz-olivera
Oral presentation
Prioritising measures to assess performance of drug treatment services: perspectives of funders, treatment providers and service users
13:20
to
14:50
Knowledge market 1 (K1)
Robert Stirling
Oral presentation
Tracking the illicit Cannabis Market during the closed Cannabis Supply Chain Experiment in Netherlands using an online Crowdsourcing Approach
13:20
to
14:50
Knowledge market 1 (K1)
Stijn Hoorens
Oral presentation
Triangulating wastewater and a prospective survey of drug consumption – new insights for policy makers
13:20
to
14:50
Knowledge market 1 (K1)
Caitlin Hughes
Oral presentation
The effects of cannabis liberalization laws on health, safety, and socioeconomic outcomes: An evidence and gap map
13:20
to
14:50
Knowledge market 1 (K1)
Eric Sevigny